Trial Profile
Study of intravenous recombinant human lymphotoxin-α derivative (rhLTα-Da) conbined with cisplatin and 5-Fluorouracil in recurrent and metastatic esophageal cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Aug 2016
Price :
$35
*
At a glance
- Drugs Lymphotoxin alpha (Primary) ; Cisplatin; Fluorouracil
- Indications Oesophageal cancer
- Focus Therapeutic Use
- Sponsors Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
- 12 Aug 2016 New trial record.